Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries

被引：1

作者：

Lee, C-K. ^{[1
]}

Yoo, C. ^{[2
]}

Park, S. J. ^{[3
]}

Kim, H. ^{[4
,17
]}

Korphaisarn, K. ^{[5
]}

Kim, J. W. ^{[6
,11
]}

Chen, S-C. ^{[7
]}

Kim, I. ^{[8
]}

Kim, M. ^{[9
]}

Chan, S. L. ^{[10
]}

Kim, J. W. ^{[6
,11
]}

Tai, D. W. M. ^{[12
]}

Oh, S. B. ^{[13
]}

Chen, C-T. ^{[14
]}

Bae, W. K. ^{[15
,16
]}

Kim, H. ^{[4
,17
]}

Hong, J. Y. ^{[18
]}

Choi, H. J. ^{[1
,19
]}

Chon, H. J.

Lee, M. A. ^{[20
]}

机构：

[1] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[2] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea

[3] Catholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

[4] Ulsan Univ Hosp, Div Hematol Oncol, Dept Internal Med, Ulsan, South Korea

[5] Mahidol Univ, Fac Med, Div Med Oncol, Dept Med,Siriraj Hosp, Bangkok, Thailand

[6] Seoul Natl Univ, Internal Med, Bundang Hosp, Seongnam, South Korea

[7] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan

[8] Inje Univ, Div Oncol, Dept Internal Med, Haeundae Paik Hosp, Busan, South Korea

[9] Gangneung Asan Hosp, Med Oncol Dept, Kangnung, South Korea

[10] Chinese Univ Hong Kong, Clin Oncol Dept, Sha Tin, Sino Bldg, Hong Kong, Peoples R China

[11] Korea Univ Anam Hosp, Dept Hemato oncol, Seoul, South Korea

[12] NCCS Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[13] Pusan Natl Univ, Internal Med, Yangsan Hosp, Yangsan, South Korea

[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Hsin Chu Branch, Hsinchu, Taiwan

[15] Chonnam Natl Univ, Div Hematol & Oncol, Med Sch, Hwasun, South Korea

[16] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea

[17] Chonnam Natl Univ Hwasun Hosp, Hwasun, South Korea

[18] Chungbuk Natl Univ Hosp, Hematol Oncol, Cheonju-si, South Korea

[19] Samsung Med Ctr SMC, Div Hematol Oncol, Seoul, South Korea

[20] Catholic Univ Korea, Internal Med Dept, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

970P

引用

页码：S603 / S603

页数：1

共 50 条

[41] First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison
Mahn, Robert
Glueer, Oscar Andre
Sadeghlar, Farsaneh
Moehring, Christian
Zhou, Taotao
Anhalt, Thomas
Monin, Malte Benedikt
Kania, Alexander
Glowka, Tim R.
Feldmann, Georg
Brossart, Peter
Kalff, Joerg C.
Schmidt-Wolf, Ingo G. H.
Strassburg, Christian P.
Gonzalez-Carmona, Maria A.
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 81 - 94
[42] SPADE: Design of a real-world observational study of avelumab first-line maintenance (1LM) in advanced urothelial carcinoma in the Asia-Pacific region
Oliveira, Niara
Su, Po Jung
Park, Se Hoon
Tsai, Yu Chieh
Kim, Miso
Wu, Wen Jeng
Gao, Seasea
Shin, Sang Joon
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 97 - 97
[43] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
Sae Yumita
Sadahisa Ogasawara
Miyuki Nakagawa
Susumu Maruta
Tomomi Okubo
Norio Itokawa
Yotaro Iino
Masamichi Obu
Yuki Haga
Atsuyoshi Seki
Tadayoshi Kogure
Takamasa Ishino
Keita Ogawa
Kisako Fujiwara
Terunao Iwanaga
Naoto Fujita
Takafumi Sakuma
Ryuta Kojima
Hiroaki Kanzaki
Keisuke Koroki
Masanori Inoue
Kazufumi Kobayashi
Soichiro Kiyono
Masato Nakamura
Naoya Kanogawa
Tomoko Saito
Takayuki Kondo
Ryo Nakagawa
Shingo Nakamoto
Ryosuke Muroyama
Tetsuhiro Chiba
Ei Itobayashi
Masanori Atsukawa
Yoshihiro Koma
Ryosaku Azemoto
Kenji Ito
Hideaki Mizumoto
Jun Kato
Naoya Kato
BMC Gastroenterology, 23
[44] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
Yumita, Sae
Ogasawara, Sadahisa
Nakagawa, Miyuki
Maruta, Susumu
Okubo, Tomomi
Itokawa, Norio
Iino, Yotaro
Obu, Masamichi
Haga, Yuki
Seki, Atsuyoshi
Kogure, Tadayoshi
Ishino, Takamasa
Ogawa, Keita
Fujiwara, Kisako
Iwanaga, Terunao
Fujita, Naoto
Sakuma, Takafumi
Kojima, Ryuta
Kanzaki, Hiroaki
Koroki, Keisuke
Inoue, Masanori
Kobayashi, Kazufumi
Kiyono, Soichiro
Nakamura, Masato
Kanogawa, Naoya
Saito, Tomoko
Kondo, Takayuki
Nakagawa, Ryo
Nakamoto, Shingo
Muroyama, Ryosuke
Chiba, Tetsuhiro
Itobayashi, Ei
Atsukawa, Masanori
Koma, Yoshihiro
Azemoto, Ryosaku
Ito, Kenji
Mizumoto, Hideaki
Kato, Jun
Kato, Naoya
BMC GASTROENTEROLOGY, 2023, 23 (01)
[45] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Mara Persano
Margherita Rimini
Toshifumi Tada
Goki Suda
Shigeo Shimose
Masatoshi Kudo
Jaekyung Cheon
Fabian Finkelmeier
Ho Yeong Lim
Lorenza Rimassa
José Presa
Gianluca Masi
Changhoon Yoo
Sara Lonardi
Francesco Tovoli
Takashi Kumada
Naoya Sakamoto
Hideki Iwamoto
Tomoko Aoki
Hong Jae Chon
Vera Himmelsbach
Tiziana Pressiani
Takumi Kawaguchi
Margarida Montes
Caterina Vivaldi
Caterina Soldà
Fabio Piscaglia
Atsushi Hiraoka
Takuya Sho
Takashi Niizeki
Naoshi Nishida
Christoph Steup
Massimo Iavarone
Giovanni Di Costanzo
Fabio Marra
Mario Scartozzi
Emiliano Tamburini
Giuseppe Cabibbo
Francesco Giuseppe Foschi
Marianna Silletta
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5591 - 5602
[46] Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Shen, Xiao
Zhang, Jin-Xing
Liu, Jin
Liu, Sheng
Shi, Hai-Bin
Cheng, Yuan
Zhang, Qing-Qiao
Yin, Guo-Wen
Zu, Qing-Quan
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1993 - 2003
[47] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Rimassa, Lorenza
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Tovoli, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Pressiani, Tiziana
Kawaguchi, Takumi
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Piscaglia, Fabio
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Iavarone, Massimo
Di Costanzo, Giovanni
Marra, Fabio
Scartozzi, Mario
Tamburini, Emiliano
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5591 - 5602
[48] First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Fujii, Yasutoshi
Kawaoka, Tomokazu
Shirane, Yuki
Miura, Ryoichi
Nakahara, Hikaru
Yamaoka, Kenji
Uchikawa, Shinsuke
Fujino, Hatsue
Ono, Atsushi
Murakami, Eisuke
Miki, Daiki
Hayes, Nelson Clair
Tsuge, Masataka
Nakamura, Yuko
Awai, Kazuo
Oka, Shiro
ONCOLOGY, 2024,
[49] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
Su, Dan
Wu, Bin
Shi, Lizheng
JAMA NETWORK OPEN, 2021, 4 (02)
[50] Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study
Kato, Daisuke
Suzuki, Takanori
Matsuura, Kentaro
Okayama, Kohei
Okumura, Fumihiro
Nagura, Yoshihito
Sobue, Satoshi
Hayashi, Katsumi
Kusakabe, Atsunori
Hasegawa, Izumi
Matoya, Sho
Mizoshita, Tsutomu
Kimura, Yoshihide
Kondo, Hiromu
Ozasa, Atsushi
Kawamura, Hayato
Fujiwara, Kei
Nojiri, Shunsuke
Kataoka, Hiromi
ONCOLOGY, 2024,

← 1 2 3 4 5 →